OSHAI
This asset is not currently listed on any markets available through Pearler. The information on this page may be inaccurate or out of date.
🇦🇺 ASX
📈 Performance
💵 Cost
🍃 Esg
🤓 Advanced
👨👩👧👦 Community
📈
N/A
Annual Growth
5 years average annual growth
💵
$ 500
Minimum Order
Due to regulatory requirements
🌏
0
Pearlers Invested
Since January 2020
📈 Performance
Price History
N/A
1M
All Time
Graph
Table
Performance graph isn't available yet for this share
Unsure how much or often to invest?
🗓️ Investing frequency calculator
Determine the investment frequency needed to reach your goals
Try it out →💵 Investing amount calculator
Determine the recurring investment needed to reach your goals
Try it out →⏱️ Investing duration calculator
Determine how long you will need to invest to reach your goals
Try it out →💵 Costs
💼
N/A
Management Fee
Included in unit price, not charged by Pearler
💸
Want to know the long term costs?
Calculate the historic long term costs to hold your investments
💸 Net fee calculator🤓 Advanced information
Technical Info
👩👩👦 Community Insights
How our community is investing
🌏 Pearlers invested in OSHAI
0
📊 Total Capital Earnings
N/A
🔃 Average investment frequency
N/A
💵 Average investment amount
N/A
⏰ Last time a customer invested in OSHAI
N/A
OSHAI investor breakdown
💵 Income of investors
More than 200k
150k - 200k
100k - 150k
50k - 100k
Less than 50k
👶 Age of investors
18 - 25
26 - 34
35 - 90
🙋 Legal gender of investors
Female
Male
Pearlers who invest in OSHAI also invest in...
Want more shares? Try these...
OncoSil Medical Ltd. develops and commercializes neurology services, including those for pancreatic cancer. The company is headquartered in Macquarie, New South Wales. The company went IPO on 2005-08-15. The firm is focused on the development and commercialization of its lead product candidate, the OncoSil localized radiation therapy for the treatment of pancreatic and distal cholangiocarcinoma. The firm has developed a cancer treatment device, the OncoSil brachytherapy device, which is a critical component of a brachytherapy treatment for locally advanced unresectable pancreatic cancer. The OncoSil device delivers a targeted intratumoral placement of Phosphorous-32 (32P) in the treatment of locally advanced unresectable pancreatic cancer. The OncoSil device has received a device designation in the European Union, United Kingdom and United States for the treatment of locally advanced unresectable pancreatic cancer in combination with chemotherapy.
🙌 Performance (5Yr p.a)
-18.68%
📊 Share price
$0.01 AUD
🔭 LIFE SCIENCES TOOLS & SERVICES
